PSA Screening Rates in Older Men Vary Considerably

Share this content:
Rates of PSA Screening in Older Men Vary Among Doctors
Rates of PSA Screening in Older Men Vary Among Doctors

(HealthDay News) -- Prostate-specific antigen (PSA) screening rates in older men vary considerably among primary care physicians (PCPs), according to a research letter published in the Oct. 16 issue of the Journal of the American Medical Association.

In an effort to assess variation in PSA screening rates according to physician, Elizabeth Jaramillo, M.D., of the University of Texas Medical Branch in Galveston, and colleagues analyzed Medicare data for 61,351 men aged 75 years or older who were seen by 1,963 PCPs.

The researchers found that 28.8% of the men received PSA screening ordered by their PCPs. Rates of PSA screening were significantly greater than the mean rate (49.8%) in 24.2% of PCPs and significantly lower than the mean rate (6.1%) in 16.0% of PCPs. About 27% of the variance in whether a man received PSA screening was explained by which PCP was providing his care.

"No organization recommends PSA screening in men older than 75 years," the authors write. "The high variability among PCPs in ordering PSA screening for older men requires additional study to understand its causes. It has been suggested that over-testing rates be included as quality measures of PCPs. Medicare data can be used to generate such measures."

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs